Anixa Biosciences Inc. has announced the completion of the transfer of the Investigational New Drug application $(IND)$ for its breast cancer vaccine from Cleveland Clinic, making Anixa the sponsor for future development and clinical trials. The company reported that enrollment for the Phase 1 clinical trial of the vaccine is complete, with encouraging immune response and safety data observed. Results from the Phase 1 trial were presented at the San Antonio Breast Cancer Symposium on December 11. Anixa plans to advance the vaccine into a Phase 2 clinical trial, utilizing multiple clinical sites, including Cleveland Clinic. The vaccine targets α-lactalbumin, a protein expressed in many forms of breast cancer, and is being developed in collaboration with Cleveland Clinic.